-
Dr. Salomon Manier: Navigating the Medical Seas, Innovating and Upgrading Treatment Plans for TIE-NDMM Patients
Recently, the 11th Sino-French Hematology Academic Conference of the Chinese Medical Doctor Association was successfully held in Tianjin, attracting hundreds of domestic and international authoritative experts and scholars in the field of hematology. During the conference, “Hematology Frontier” specially invited Dr. Salomon Manier from the Hematology Department of Lille University Hospital in France to discuss…
-
ILCA Chair Interview | Dr. Tim Meyer: Focusing on Advances in Liver Cancer Treatment and Shaping Future Progress
Q1: Could you introduce some of the key topics or highlights of this ILCA conference? Dr. Tim Meyer: The International Liver Cancer Association (ILCA) is a prominent multidisciplinary association that…
-
CSCO 2024 | Dr. Lei Tang: Advancements in Modern Imaging Support Immunotherapy Evaluation for Gastric Cancer
The 27th Annual Conference of the Chinese Society of Clinical Oncology (CSCO) took place in Xiamen from September 25–29, 2024. This year’s theme, “Patient-Centered, Sharing the Future,” brought together groundbreaking research and developments. Dr. Lei Tang from Peking University Cancer Hospital delivered an insightful presentation on the current state and challenges of imaging in evaluating…
-
ASCO GI 2024 | Dr. Zhi Peng Discusses Immunotherapy and Targeted Chemotherapy for Gastric Cancer
The 2024 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2024) took place in San Francisco from January 18-20, gathering top experts from around the world to share the latest advances in gastrointestinal cancer research. Dr. Zhi Peng from Peking University Cancer Hospital presented two studies (Abstracts 312 and 317) in the poster session, showcasing the contributions…
-
ASCO Plenary Series | Dr. Ruihua Xu and Dr. Florian Lordick: FRUTIGA Study Offers New Hope for Second-Line Treatment of Advanced Gastric Cancer
The field of second-line treatment for advanced gastric cancer is a current focal point in oncology research. On February 6, 2024, during the ASCO Plenary Series, Dr. Ruihua Xu from Sun Yat-sen University Cancer Center presented findings from the FRUTIGA study (NCT03223376), a phase III trial conducted in China evaluating the efficacy of fruquintinib combined…
-
SIBCS| Dr. Virginia Kaklamani’s Insights on Post-CDK4/6i Management of HR+ Advanced Breast Cancer at MD Anderson
On October 18, 2024, the 18th National Breast Cancer Conference and the 19th Shanghai International Breast Cancer Forum grandly opened, gathering significant global advancements in breast cancer. In the era following CDK4/6 inhibitors for hormone receptor-positive (HR+) breast cancer, targeted endocrine therapies based on the PIK3CA/AKT1/PTEN pathway have brought new hope to patients. At this…
-
Treatment Options for MET-Amplified EGFR-Mutated NSCLC Following Third-Generation TKI Resistance
For patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), dual inhibition of EGFR and MET may be the most effective strategy after disease progression on osimertinib, particularly for patients with MET gene amplification (METamp). Dr. Benjamin Besse, Dr. Lodovica Zullo, and Dr. Jordi Remon from the Gustave Roussy Institute analyze therapeutic strategies for METamp-driven…
-
Dr. Benlong Yang: New Frontiers in Breast Reconstruction – Prevention and Management of Implant Complications
Breast reconstruction surgery offers hope for patients to regain confidence and beauty in the field of breast cancer treatment. With advances in medical technology, implant-based breast reconstruction has become a mainstream choice. However, complications related to implants remain a key concern for both surgeons and patients. At the 16th Shanghai Breast Reconstruction Conference, Dr. Benlong…
Connecting Medical Expertise through Media